SyB C-1101

DRUG3 trials

Sponsors

SymBio Pharmaceuticals

Conditions

Myelodysplastic Syndrome

Phase 1

Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study

CompletedNCT02002936

SymBio PharmaceuticalsMyelodysplastic Syndrome

Start: 2013-08-31End: 2014-12-31Updated: 2017-02-23

Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)

CompletedNCT02014051

SymBio PharmaceuticalsMyelodysplastic Syndrome

Start: 2013-03-31End: 2014-11-30Updated: 2022-11-21

Study of SyB C-1101 in Patients With Myelodysplastic Syndrome

CompletedNCT03495167

SymBio PharmaceuticalsMyelodysplastic Syndrome

Start: 2017-10-06End: 2019-05-28Updated: 2022-11-16